Girentuximab (G250) 是一种嵌合单克隆抗体,可与碳酸酐酶 IX (CAIX) 结合,碳酸酐酶 IX 是一种在透明细胞肾细胞癌 (ccRCC) 中广泛表达的细胞表面糖蛋白。
生物活性 | Girentuximab (G250) is a chimeric monoclonal antibody that bindscarbonic anhydraseIX (CAIX), a cell surfaceglycoproteinubiquitously expressed in clear cell renal cell carcinoma (ccRCC)[1]. |
体外研究 (In Vitro) | Girentuximab is an IgG1 κ light chain chimeric version of a murine monoclonal antibody (mAb) and recognizes the antigen CAIX[1].
|
Clinical Trial | |
性状 | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |